Stoke Therapeutics Inc.

NASDAQ: STOK · Real-Time Price · USD
17.56
0.39 (2.27%)
At close: Aug 15, 2025, 10:19 AM

Stoke Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
36.55M 8.78M 12.4M n/a
Cost of Revenue
n/a 4.73M 3.54M 2.23M
Gross Profit
36.55M 8.78M 12.4M -2.23M
Operating Income
-101.37M -114.77M -104.36M -86.06M
Interest Income
12.64M 9.91M 3.12M 120K
Pretax Income
-88.98M -104.7M -101.07M -85.81M
Net Income
-88.98M -104.7M -101.07M -85.81M
Selling & General & Admin
48.79M 41.32M 38.92M 31.9M
Research & Development
89.13M 82.23M 77.84M 54.17M
Other Expenses
n/a n/a n/a -2.23M
Operating Expenses
137.93M 123.55M 116.76M 83.83M
Interest Expense
n/a n/a n/a 120K
Selling & Marketing Expenses
n/a n/a n/a n/a
Cost & Expenses
137.93M 123.55M 116.76M 86.06M
Income Tax Expense
n/a n/a -7.96M -1.09M
Shares Outstanding (Basic)
54.01M 43.99M 38.9M 36.74M
Shares Outstanding (Diluted)
54.01M 43.99M 38.9M 36.74M
EPS (Basic)
-1.65 -2.38 -2.6 -2.34
EPS (Diluted)
-1.65 -2.38 -2.6 -2.34
EBITDA
-99.19M -112.3M -102.81M -83.58M
EBIT
-101.37M -114.77M -104.36M -85.81M
Depreciation & Amortization
2.18M 2.47M 1.55M 2.23M